Glycosylated Cell Penetrating Peptides, GCPPs by Gallego Gómez, Iván et al.
S1	
	
Glycosylated Cell Penetrating Peptides, GCCPs 
Iván Gallego,[a] Alicia Rioboo,[a] Dr. José J. Reina,[a] Bernardo Díaz,[b] Dr. Ángeles Canales,[c] Dr. 
F. Javier Cañada,[b,c] Dr. Jorge Guerra-Varela,[d] Prof. Laura Sánchez,[d] Dr. Javier 
Montenegro*[a] 
 
[a] Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química 
Orgánica, Universidade de Santiago de Compostela, Campus Vida, 15782 Santiago de Compostela, Spain. *e-mail: 
javier.montenegro@usc.es 
[b] Centro de Investigaciones Biológicas (CIB) del CSIC, C/Ramiro de Maetzu 9, CP 28040, Madrid. 
[c] Departamento de Biología Estructural y Química, Fac. Ciencias Químicas Univ. Complutense de Madrid, Avd/ 
Complutense s/n, CP. 28040, Madrid. 
[d] Departamento de Zooloxía, Xenética e Antropoloxía Física. Facultade de Veterinaria Universidade de Santiago de 
Compostela, 27002, Lugo, Spain. 
	
Table of Contents 
Supporting figures  ............................................................................... S2 
Materials and methods  ........................................................................ S6 
Abbreviations ........................................................................................ S7 
General protocols ................................................................................. S7 
 General protocols for the SPPS ............................................................................... S7 
 General protocol for N-terminal functionalization ..................................................... S7 
 General protocol for peptide cleavage ..................................................................... S8 
 General protocol for ligand coupling ........................................................................ S8 
Synthesis of peptides ........................................................................... S8 
 Synthesis of TmP(Man)2 .......................................................................................... S8 
 Synthesis of TmP(Gal)2 ........................................................................................... S8 
 Synthesis of TmP(NAG)2 ......................................................................................... S8 
 Synthesis of TmP(Glu)2 ........................................................................................... S8 
 Synthesis of TmP(Man3)2 ......................................................................................... S9 
 Synthesis of TmP(Acetone)2 .................................................................................. S10 
General procedure for circular dichroism ........................................ S10 
NMR measurements ............................................................................ S10 
Cells lines and culture ........................................................................ S10 
Cell viability: MTT assay ..................................................................... S11 
General protocol for flow cytometry ................................................. S11 
Zebrafish experiments ........................................................................ S11 
Supporting figures for characterization ............................................ S13 





















Figure S3. These pictures show a dose-response microscopy images of TmP(Acetone)2 
internalization capacity in HeLa cells. (0,5, 1, 3, 5) µM of this control peptide in HKR buffer was 
incubated for 30 min and 37ºC. Scale bar: 25 µm. 
 
Figure S4. CD spectra of TmP(Gal)2, TmP(NAG)2, TmP(Man3)2 and TmP(Acetone)2 in different 
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Figure S5. MTT assay. Cytotoxicity of each GCPP and control peptide TmP(Acetone)2 were 
checked using MTT assay. HeLa cells were incubated at 5 µM during 30 min and 37ºC. 
 
 
Figure S6. A) 2D NOESY spectrum of TmP(Man)2, acquired in phosphate buffer 20 mM 






Figure S7. Dose-response microscopy images of TmP(Glu)2 internalization capacity in HeLa 
cells. (3, 5, 7, 10) µM of this peptide in DMEM and DMEM/FBS (10%) was incubated for 30 min 
and 37ºC. Scale bar: 25 µm. A) Dose-response confocal experiments. B) Flow cytometry. 
 
Figure S8. Images of zebra fish showing no fluorescence of the TAMRA control and strong yolk 
internalization of TmP(Acetone)2 24 hours post treatment. 96 hours post treatment  the 
TmP(Acetone)2 did not cross the yolk and higher concentrations of this peptide (> 3 µM) showed 
strong toxicity and complete morbidity to the zebrafish. In vivo experiments were performed at 1 
µM with Tm (TAMRA) and control peptide TmP(Acetone)2. Scale bar 500 µm (24 hpt) and 250 
µm (96 hpt). 
Materials and methods 
Commercially available Fmoc-Rink Amide AM resin, N-HBTU and Fmoc-L-Lys(Mtt)-OH were 
used as obtained from Iris. [Tert-butoxycarbonyl)aminooxy]acetic acid were purchased from TCI 
Chemicals. Fmoc-L-Leu-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-6Ahx-OH, Heparin sodium salt were 
purchased from Sigma-Aldrich®. 5(6)-Carboxytetramethlyrhodamine succinimidyl ester were 
purchased from Carbosynth. Hoechst 33342 Trihydrochloride Trihydrate were purchased in 
ThermoFisher. Deuterated solvents (D2O) were from EMD Millipore Corporation. N,N-
Dimethylformamide, for peptide synthesis, was purchased from Scharlau. All the other solvents 
were HPLC grade, purchased from Sigma-Aldrich® or Fisher Scientific® and used without 
further purification.  
High-performance liquid chromatography coupled with mass spectrometry (HPLC-MS) analyses 
were carried out on Agilent Technologies 1260 Infinity II associated with a 6120 Quadrupole LC-
MS using an Agilent SB-C18 column or an DIONEX Ultimate 3000 U-HPLC+ (Thermo Scientific) 
with an Acclaim RSLC 120-C18 column with Solvent A: Solvent B gradients between 5:95 
(Solvent A: H2O with 0.1% TFA; Solvent B: CH3CN with 0.1% TFA). High-performance liquid 
chromatography (HPLC) preparative purification was carried out on Waters 1525 composed by 
a binary pump with a dual Waters 2489 detector with a Phenomenex Luna C18(2) 100Å 
column. A JASCO with an Agilent Eclipse XDB-C18 column was used for semi-preparative 
purification using gradient 5:95 (Solvent A: H2O with 0.1% TFA; Solvent B: CH3CN with 0.1% 
TFA). Nuclear Magnetic Resonance (NMR) spectra were recorded on either a Varian Mercury 






















































































































units) referenced to the following solvent signals: D2O δH 4.79. Spin multiplicities are reported 
as a singlet (s), doublet (d), triplet (t) with coupling constants (J) given in Hz, or multiplet (m). 
Accurate mass determinations (HR-MS) using ESI-MS were performed on a Sciex QSTAR 
Pulsar mass spectrometer and are reported as mass-per-charge ratio (m/z). Recalculation of 
the labelled peptides concentrations was performed by measuring the absorbance on a 
Biochrom Libra S60 UV-VIS Spectrophotometer. Circular Dichroism (CD) measurements were 
performed with a Jasco J-1100 CD Spectrometer equipped with a Jasco MCB-100 Mini 
Circulation Bath. Cell microscopy images were acquired with an Andor Zyla 4.2 digital camera 
mounted on a Nikon Eclipse Ti-E epifluorescence microscope and with a Leica SP5 confocal 




Peptide Abbreviations: TmP(X)2 (Tm = TAMRA and X = Man, Glu, Acetone, Man3, Gal and 
NAG); Aa: Amino acid; Arg: Arginine; Boc: tert-Butoxycarbonyl; CPP: Cell-Penetrating Peptide; 
DCM: Dichloromethane; DIEA: N,N-Diisopropylethylamine; DMF: N,N-Dimethylformamide; FBS: 
Fetal Bovine Serum; Fmoc: 9-fluorenylmethoxycarbonyl; HFIP: 1,1,1,3,3,3-Hexafluoro-2-
propanol; HKR: HEPES-Krebs-Ringer buffer; HRMS (ESI): High resolution mass spectrometry 
(electrospray ionization); Lys: Lysine; Mtt: 4-Methyltrityl; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; N-HATU: N-[(Dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-
ylmethylene]-N-methyl methanaminiun hexafluorophosphate N-oxide; N-HBTU: N-
[(1HBenzotriazol-1-yl)4-(dimethylamino)methylene]-N-methyl methanaminiumhexafluoro 
phosphate N-oxide; Pbf: 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl; RP: Reverse 
Phase; SPPS: Solid Phase Peptide Synthesis; TAMRA: 5(6)-Carboxytetramethlyrhodamine 
succinimidyl ester; TFE: Trifluoroethanol; TIS: Triisopropylsilane; TNBS: 2,4,6-
Trinitrobenzenesulfonic acid; 6Ahx: 6-aminohexanoic acid. DMEM: Dulbecco's Modified Eagle 
Medium. FBS: Fetal Bovine Serum. 
General protocols 
General protocols for the SPPS 
All peptides were synthesized by manual Fmoc solid-phase peptide synthesis[1,2] using Rink 
Amide resin (loading 0.71 mmol/g). The resin (0.1 mmol) was swelled in DMF (peptide synthesis 
grade, 2 mL) for 20 min in a peptide synthesis vessel prior synthesis. Coupling cycle consisted 
of the removal of Fmoc protecting group with a solution of piperidine in DMF (20%, 2mL) for 10 
min and then the mixture was filtered and the resin was washed with DMF (3x2 mL, 1 min). The 
amino acid coupling was carried out by treatment with a solution of α-amino acids (4 equiv), N-
HBTU (3.95 equiv) in DMF (2 mL), which was mixed with DIEA (0.195 M solution in DMF, 1.2 
equiv) 1 min before the addition and the resulting mixture was shaken by bubbling Ar for 15 min. 
Finally, the resin was washed with DMF (3x2 mL, 1 min). The efficiency of each amino acid 
coupling and deprotection was monitored employing the TNBS test[3]. Once the linear peptide 
was finished, the ending protocol used was “linker coupling”, after Fmoc cleavage with 
piperidine/DMF (20%, 2mL), the linear peptide was treated with a solution of N-Fmoc-6-
aminohexanoic acid (4 equiv), N-HBTU (3.95 equiv) and DIEA (0.195 M solution in DMF, 1.2 
equiv) in DMF.  
The resin was washed with DCM (2x2 mL, 5 min), and the Mtt protecting group was selectively 
removed by mechanical shaking of the resin with a mixture of DCM/HFIP/TFE/TIS (6.5:2:1:0.5, 
2x2 mL, 2 h). Finally, the mixture was filtered and the resin was washed with DCM (2x2 mL, 2 
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min) and DMF (2 mL, 20 min). A solution of [(tert-butoxycarbonyl) aminooxy] acetic acid (2.5 
equiv per free amine) and N-HATU (2.5 equiv) in DMF (1 mL) was added to the resin followed 
by the dropwise addition of a solution of DIEA (4 equiv) in DMF (0.5 mL). The resin was shaken 
by bubbling Ar for 30 min and finally washed with DMF (3x2 mL, 2 min) and DCM (3x2 mL, 2 
min). 
General protocol for N-terminal functionalization 
Fluorescently labelled peptides: the Fmoc-protecting group of the previously attached linker was 
removed by using a solution of piperidine in DMF (20%, 4 mL) for 15 min and the resin was 
washed with DMF (3x3 mL). The coupling was carried out by the addition of a solution of 5(6)-
Carboxytetramethylrhodamine succinimidyl ester (1 equiv) and DIEA (0.195 M, 1 equiv) in DMF 
(2 mL) and the mixture was stirred by bubbling Ar for 30 min. Finally, the resin was washed with 
DMF (3x3 mL) and DCM (3x3 mL). 
General protocol for peptide cleavage 
Finally, peptides were deprotected and cleaved from the resin by standard TFA cleavage 
procedure at rt by using TFA/DCM/H2O/TIS (90:5:2.5:2.5, 1 mL per 70 mg of resin) for 2 h. 
Then, the mixture was filtered, washed with TFA (1 mL) and the peptide was precipitated with 
ice-cold Et2O (25 mL). The precipitate was centrifuged and dissolved in H2O (5 mL). Peptides 
were obtained following the previously described procedure, and were treated with the different 
ligands without purification. 
General protocol for ligand coupling 
A solution of peptide in H2O (5 mM) was reacted with a solution of corresponding aldehyde 
ligands[4] (2 equiv. per alkoxyamine) in H2O (120 mM) for 5 min. Then, peptides were purified by 
RP-HPLC for removing the ligand excess. The purification was carried by Agilent Eclipse XDB-
C18 column H2O (0.1% TFA)/CH3CN (0.1% TFA), 95:5→5:95 (5→35 min)] with a binary 
gradient of Solvent A and Solvent B, the collected fractions were lyophilized and stored at -20 
°C. Purity and identity were confirmed by HPLC, 1H-NMR and low and high resolution mass 
spectrometry. 
Synthesis of peptides 
Synthesis of TmP(Man)2 
Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide with two 
α-D-mannoses, TmP(Man)2 was obtained after RP-HPLC purification [Agilent Eclipse XDB-C18, 
9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] with an overall yield 
of 6% (17 mgs) and 99% purity. Rt 7.62 min (Fig. S6) [RP-HPLC Agilent SB-C18 column, H2O 
(0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. The spectroscopic data matched 
those previously reported.[2] 1H-NMR (500 MHz, D2O, δ): 8.21 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 
7.58 (m, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.11 (t, J = 9.9 Hz, 2H), 6.97 (m, 1H), 6.83 (d, J = 9.6 Hz, 
2H), 6.75 (s, 2H), 4.80-4.73 (m, 2H), 4.68 (s, 4H), 4.40 (d, J = 24.1 Hz, 4H), 4.28-3.96 (m, 13H), 
3.87-3.24 (m, 12H), 3.13 (s, 12H), 3.10-2.95 (m, 16H), 2.91-2.80 (m, 2H), 2.25 (t, J = 7.1 Hz, 
2H), 1.79-1.11 (m, 57H), 0.87-0.67 (m, 30H).  MS (ESI, H2O): 1657 (7, [M+2H+4TFA]+2), 1599 
(17, [M+2H+3TFA]+2), 1542 (15, [M+2H+2TFA]+2), 1027 (100, [M+3H+2TFA]+3), 989 (99, 
[M+3H+TFA]+3), 953 (28, [M+3H+]+3), 743 (62, [M+4H+TFA]+4), 716 (53, [M+4H]+4). HRMS 
(ESI): Calculated for C129H217N39O34: 1428.3220; found: 1428.3209 ([M+2H]+2). 
Synthesis of TmP(Gal)2 
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Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide with two 
β-D-galactoses, TmP(Gal)2 was obtained after RP-HPLC purification [Agilent Eclipse XDB-C18, 
9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] with an overall yield 
of 9% (26 mgs) and 97% purity. Rt 7.81 min (Fig. S7) [RP-HPLC Agilent SB-C18 column, H2O 
(0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. 1H-NMR (500 MHz, D2O, δ): δ 8.47 
(s, 1H), 8.08-7.96 (m, 1H), 7.63-7.53 (m, 1H), 7.25 (s, 1H), 7.06-6.91 (m, 2H), 6.89-6.83 (m, 
1H), 6.79-6.62 (m, 2H), 6.57 (s, 2H), 4.81-4.68 (m, 4H), 4.66-4.58 (m, 4H), 4.38 (s, 2H), 4.28-
3.90 (m, 13H), 3.89-3.31 (m, 12H), 3.19-3.05 (m,16H), 3.04 (s, 12H), 2.91-2.71 (m, 2H), 2.37-
2.11 (m, 2H), 1.98-1.04 (m, 57H), 0.90-0.53 (m, 30H). MS (ESI, H2O): 1599 (7, 
[M+2H+3TFA]+2), 1543 (8, [M+2H+2TFA]+2), 1029 (75, [M+3H+2TFA]+3), 991 (100, 
[M+3H+TFA]+3), 953 (20, [M+3H]+3), 744 (35, [M+4H+TFA]+4), HRMS (ESI): Calculated for 
C129H218N39O34: 952.5504; found: 952.5499 ([M+3H]+3). 
 
Synthesis of TmP(NAG)2 
Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide with two 
N-acetyl-β-D-glucosamine, TmP(NAG)2 was obtained after RP-HPLC purification [Agilent 
Eclipse XDB-C18, 9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] 
with an overall yield of 9% (26 mgs) and 98% purity. Rt 7.63 min (Fig. S8) [RP-HPLC Agilent 
SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. 1H-NMR (500 
MHz, D2O, δ): 8.37 (s, 1H), 8.08 (s, 1H), 7.97-7.86 (m, 1H), 7.77 (s, 1H), 7.49 (t, J = 5.4 Hz, 
2H), 6.97-6.91 (m, 1H), 6.91-6.81 (m, 2H), 6.67-6.52 (m, 2H), 4.54-4.46 (m, 2H), 4.47-4.32 (m, 
19.7 Hz, 4H), 4.29-3.89 (m, 13H), 3.77-3.29 (m, 12H), 3.09 (s, 12H), 3.08-2.95 (m, 16H), 2.85-
2.71 (m, 2H), 2.34-2.22 (m, 2H), 1.94-1.85 (m, 6H), 1.81-1.29 (m, 57H), 0.86-0.57 (m, 30H). MS 
(ESI, H2O): 1638 (10, [M+2H+3TFA]+2), 1581 (5, [M+2H+2TFA]+2), 1055 (100, [M+3H+2TFA]+3), 
1016 (80, [M+3H+TFA]+3), 979 (15, [M+3H]+3),762 (30, [M+4H+TFA]+4), 734 (25, [M+4H]+4), 
HRMS (ESI): Calculated for C133H224N41O34: 979.9014; found: 979.9011 ([M+3H]+3). 
Synthesis of TmP(Glu)2 
Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide with two 
β-D-glucose, TmP(Glu)2 was obtained after RP-HPLC purification [Agilent Eclipse XDB-C18, 
9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] with an overall yield 
of 15% (42 mgs) and 99% purity. Rt 7.59 min (Fig. S9) [RP-HPLC Agilent SB-C18 column, H2O 
(0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. 1H-NMR (300 MHz, D2O, δ): 8.21 (s, 
1H), 7.96-7.91 (m, 1H), 7.83 (s, 1H), 7.69-7.57 (m, 1H), 7.19-7.12 (m, 2H), 7.09-7.00 (m, 1H), 
6.75 (s, 2H), 6.65-6.57 (m, 2H), 4.46 (s, 2H), 4.41-4.33 (m, 4H), 4.27-4.00 (m, 13H), 3.86-3.27 
(m, 12H), 3.13 (s, 12H), 3.10-3.02 (m, 16H), 2.76 (d, J = 7.4 Hz, 2H), 2.31-2.18 (m, 2H), 1.96-
1.09 (m, 57H), 0.95-0.60 (m, 30H). MS (ESI, H2O): 1598 (10, [M+2H+3TFA]+2), 1544 (8, 
[M+2H+2TFA]+2), 1029 (50, [M+3H+2TFA]+3), 991 (100, [M+3H+TFA]+3), 953 (23, [M+3H]+3), 
744 (47, [M+4H+TFA]+4), 715 (43, [M+4H]+4), HRMS (ESI): Calculated for C129H218N39O34: 
952.5504; found: 952.5505 ([M+3H]+3). 
Synthesis of TmP(Man3)2 
Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide with two 
α-D-mannose trisaccharide, TmP(Man3)2 was obtained after RP-HPLC purification [Agilent 
Eclipse XDB-C18, 9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] 
with an overall yield of 11% (38 mgs) and 99% purity. Rt 7.73 min (Fig. S10) [RP-HPLC Agilent 
SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. 1H-NMR (500 
MHz, D2O, δ): 8.21 (s, 1H), 8.03-7.87 (m, 1H), 7.72-7.58 (m, 1H), 7.44-7.35 (m, 1H), 7.23-7.12 
(m, 2H), 7.04-6.95 (m, 2H), 6.95-6.86 (m, 2H), 6.83 (s, 2H), 5.07-4.93 (m, 2H), 4.86-4.70 (m, 
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4H), 4.51-4.40 (m, 4H), 4.33-4.09 (m, 13H), 4.07-3.34 (m, 62.5 Hz, 36H), 3.18 (s, 12H), 3.14-
3.03 (m, 16H), 2.94-2.78 (m, 2H), 2.36-2.11 (m, 2H), 1.95-1.03 (m, 57H), 0.95-0.58 (m, 30H). 
MS (ESI, H2O): 1244 (100, [M+3H+2TFA]+3), 1207 (78, [M+3H+TFA]+3), 1169 (10, [M+3H]+3), 
905 (55, [M+4H+TFA]+4), 604 (47, [M+6H+TFA]+6), HRMS (ESI): Calculated for C153H258N39O54: 
1168.6208; found: 1168.6204 ([M+3H]+3). 
Synthesis of TmP(Acetone)2 
Following the general protocol of the SPPS for synthesizing a TAMRA labelled peptide capped 
with acetone, TmP(Acetone)2 was obtained after RP-HPLC purification [Agilent Eclipse XDB-
C18, 9.4x250 mm, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→35 min)] with an overall 
yield of 12% (30 mgs) and 99.9% purity. Rt 8.21 min (Fig. S11) [RP-HPLC Agilent SB-C18 
column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→12 min)]. 1H-NMR (500 MHz, 
D2O, δ): 8.07-7.89 (m, 2H), 7.55 (s, 1H), 7.03 (d, J = 9.2 Hz, 2H), 6.89-6.69 (m, 4H), 4.34 (d, J = 
7.9 Hz, 4H), 4.27-3.93 (m, 13H), 3.40-3.22 (m, 2H), 3.10 (s, 12H), 3.07-2.98 (m, 16H), 2.31-2.11 
(m, 2H), 1.89-1.63 (m, 12H), 1.60-1.10 (m, 57H), 0.88-0.64 (m, 30H). MS (ESI, H2O): 1492 (8, 
[M+2H+4TFA]2+), 1434 (10, [M+2H+3TFA]2+), 1376 (8, [M+2H+2TFA]2+), 918 (100, 
[M+3H+2TFA]3+), 881 (100, [M+3H+TFA]3+), 690 (18, [M+4H+2TFA]4+), 662 (40, 
[M+4H+TFA]4+), 632 (18, [M+4H]4+). HRMS (ESI): Calculated for C119H201N39O22: 1264.2899; 
found: 1264.2902 ([M+2H]2+). 
General procedure for circular dichroism 
Circular dichroism measurements were carried out using the following settings: acquisition 
range: 300-190 nm; band width: 1.0 nm; accumulation: 3 scans; data pitch: 1 nm; CD scale: 200 
mdeg/1.0 dOD; D.I.T. (Data Integration Time): 1s; scanning mode: continuous; scanning speed: 
200 nm/min. Measurements were done from 10oC to 60oC (data interval: 10oC; temp. gradient: 
5oC /min) in a quartz cell of 0.2 cm path length at a final volume of 0.5 mL (HKR buffer or TFE) 
with a final peptide concentration of 200 µM. 
The results are expressed as the mean residue molar ellipticity [θ]MRt with units of 
degrees·cm2·dmol-1 and calculated using the equation S1: 
𝜃 !"# =
100 ∙  𝜃
𝐶 ∙ 𝑙 ∙ 𝑁!𝑜𝑓 𝑟𝑒𝑠𝑖𝑑𝑢𝑒𝑠
                      (𝑆1) 
where θ is the ellipticity (deg), C is the peptide concentration (M) and l is the cell path length 
(cm).[5,6] 
NMR measurements  
NMR experiments were acquired with 1.5 mM peptide samples prepared in phosphate buffer 20 
mM containing 30% of deuterated trifluoroethanol (TFE-d2) and 10 % of D2O. 2D-TOCSY and 
2D-NOESY spectra were acquired on a Bruker 500 MHz spectrometer at 298 K, with mixing 
times of 75 ms and 500 ms, respectively. Both experiments were recorded with 4096 data 
points in F2 and 256 data points in F1. 
Peptide assignment were carried out by using CARA software[7] and structure calculations were 
performed by using CYANA 3.0 with distance restraints derived from the experimental NOEs.[8] 
Cells lines and culture 
Cell lines were incubated at 37oC, 5% CO2, 95% humidity in an INCO 108 incubator (Memmert) 
with Dulbecco’s Modified Eagle’s Medium (4500 mg/L glucose, L-glutamine, sodium pyruvate 
S11	
	
and sodium bicarbonate; Sigma-Aldrich), supplemented with 10% fetal bovine serum (Sigma-
Aldrich) and 1% of Penicillin-Streptomycin-Glutamine Mix (Fisher). Each cell line was grown on 
four chamber glass bottom dishes and washed with HEPES–Krebs–Ringer (HKR) buffer (5mM 
HEPES, 137 mM NaCl, 2.68 mM KCl, 2.05 mM MgCl2, 1.8 mM CaCl2, pH 7.4) and nuclei were 
stained by incubation with 1µM Hoechst 33342 in HKR for 30 min. The peptide was diluted in 
HKR, DMEM or DMEM/FBS (10%) to obtain the different concentrations that were recalibrated 
by UV. Cells were incubated with the peptide for 30 min and then washed to remove excess 
peptide using an heparin solution (2x500 µL, 0.1 mg/ml) and HKR buffer (2x500 µL) before 
performing epifluorescence microscopy using a Nikon Eclipse Ti-E inverted microscope or 
confocal microscopy with a Leica SP5 microscope. Images were analyzed with ImageJ. 
Cell viability: MTT assay 
Cell viability was established by a standard MTT assay (Fig. S5). One day before the assay, a 
suspension of HeLa cells was plated in 96-well tissue culture plates (Costar 96 Flat Bottom 
Transparent Polystyrol) by adding 100 µL (150.000 cells/mL) per well. The next day, the 
medium was aspirated and cells were incubated with different concentrations of peptide diluted 
in HKR (50 µL/well). After 1 hour of incubation at 37ºC, the medium was aspirated and cells 
were washed with HKR buffer (2x100 µL/well). Then fresh medium (DMEM) containing 10% 
FBS (100 µL) was added to the cells during 3h. Control cells 100% were permorfed with only 
cell culture medium (100 µL final medium) and control cell 0% with TRITON solution. The 
viability was measured by quantifying the cellular ability to reduce the water-soluble tetrazolium 
dye 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) to its insoluble 
formazan salt as follows. MTT (5 mg/mL in PBS, 10 µL/well) was added to the wells and the 
cells were further incubated for 4 h. The supernatant was carefully removed and the water-
insoluble formazan salt was dissolved in DMSO (100 µL/well). The absorbance was measured 
at 570 nm using a microplate reader (Infinite F200pro, Tecan). Data points were collected in 
triplicate and expressed as normalized values for untreated control cells (100% and 0%). 
General protocol for flow cytometry 
One day before the assay, different cell lines were plated in 96-well tissue culture plates (Costar 
96 Flat Bottom Transparent Polystyrol) by adding 100 µL (150.000 cells/mL) per well. The next 
day, the medium was aspirated and cells were incubated with different concentrations of 
peptide (50 µL/well) in HKR buffer. After 30 min of incubation at 37ºC, the buffer was aspirated; 
cells were washed with heparin solution (1x100 µL, 0.1 mg/mL) and HKR buffer (2x100 µL). 
Finally trypsin 50 µL was added in each well and cells were incubated for 15 min at 37ºC. After 
this, 150 µL of a solution of 2% FBS and 5 mM EDTA in PBS were added to the cells. Cells 
were analyzed in a Guava EasyCyte (Millipore) cytometer and the results were processed in an 
InCyte software (GuavaSoft 3.2 Millipore). 
Zebrafish experiments 
One-year-old adult zebrafish (Danio rerio) were maintained in 30 L aquaria at a rate of 1 fish per 
liter of water on a recirculating system, in a controlled environment of 14-h light/10-h dark cycle 
at 28 ºC. Zebrafish embryos were obtained by massive spawning from breeding stocks of adult 
zebrafish. 
48 hours post-fertilization (hpf) zebrafish embryos were exposed to 1 µM concentration of 
glycopeptides (namely TmP(Gal)2 and TmP(Man3)2) in order to evaluate their uptake capacity 
into the embryo and, if possible, their biodistribution. This was possible because of fluorescence 
characteristics of glycopeptides analysed and transparency of fish embryos. Exposition took 
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place for 96 h, being fishes checked every 24 h. Pictures were taken with a Nikon AZ100 Zoom 
fluorescence microscope and analyzed with NIS Elements software (Nikon). 
The protocols used in this study were performed in compliance with the EU animal 
experimentation regulation (EU, 2010) and were approved by the Bioethics Committee for 
Animal Experimentation CEEA-LU (Universidade de Santiago de Compostela, Spain). When 

















Figure S9. A) 1H-NMR spectra in D2O of TmP(Man)2. B) RP-HPLC-C18 column, H2O (0.1% 



























































Figure S10. A) 1H-NMR spectra in D2O of TmP(Gal)2. B) RP-HPLC-C18 column, H2O (0.1% 


































































Figure S11. A) 1H-NMR spectra in D2O of TmP(NAG)2. B) RP-HPLC-C18 column, H2O (0.1% 
























































Figure S12. A) 1H-NMR spectra in D2O of TmP(Glu)2. B) RP-HPLC-C18 column, H2O (0.1% 


























































Figure S13. A) 1H-NMR spectra in D2O of TmP(Man3)2. B) RP-HPLC-C18 column, H2O (0.1% 
























































Figure S14. A) 1H-NMR spectra in D2O of TmP(Acetone)2. B) RP-HPLC-C18 column, H2O 
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